Amryt Pharma plc
AMYT
Price:
$14.7
Market Cap:
$0
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations ...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2020-07-08
Stock Exchange
NASDAQ
Ticker
AMYT
The ROE as of July 2024 (TTM) for Amryt Pharma plc (AMYT) is -9.00%
According to Amryt Pharma plc’s latest financial reports and current stock price. The company's current ROE is -9.00%. This represents a change of 325.07% compared to the average of -2.12% of the last 4 quarters.
Amryt Pharma plc (AMYT) Historical ROE (quarterly & annually)
How has AMYT ROE performed in the past?
The mean historical ROE of Amryt Pharma plc over the last ten years is -18.32%. The current -9.00% ROE has changed -50.85% with respect to the historical average. Over the past ten years (40 quarters), AMYT's ROE was at its highest in in the June 2019 quarter at 57.89%. The ROE was at its lowest in in the December 2020 quarter at -71.04%.
Average
-18.32%
Median
-37.15%
Minimum
-318.52%
Maximum
797.80%
Amryt Pharma plc (AMYT) ROE by Quarter and Year
Discovering the peaks and valleys of Amryt Pharma plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 5.18%
Maximum Annual ROE = 797.80%
Minimum Annual Increase = -558.71%
Minimum Annual ROE = -318.52%
| Year | ROE | Change |
|---|---|---|
| 2021 | -5.38% | -96.59% |
| 2020 | -158.03% | 211.85% |
| 2019 | -50.68% | -106.35% |
| 2018 | 797.80% | -558.71% |
| 2017 | -173.92% | 636.28% |
| 2016 | -23.62% | -90.21% |
| 2015 | -241.34% | 5.18% |
| 2014 | -4.57% | -7.60% |
| 2013 | -4.95% | -98.45% |
| 2012 | -318.52% | 13.54% |
Amryt Pharma plc (AMYT) Average ROE
How has AMYT ROE performed in the past?
The current ROE of Amryt Pharma plc (AMYT) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-71.36%
5-year avg
81.96%
10-year avg
-18.32%
Amryt Pharma plc (AMYT) ROE vs. Peers
How is AMYT’s ROE compared to its peers?
Amryt Pharma plc’s ROE is greater than Universe Pharmaceuticals INC (-14.22%), greater than Regencell Bioscience Holdings Limited (-39.17%), less than Indigenous Bloom Hemp Corp. (123.14%), less than Eagle Pharmaceuticals, Inc. (4.41%), less than Sangui Biotech International, Inc. (11.03%), greater than Qilian International Holding Group Limited (-16.27%), greater than IM Cannabis Corp. (-117.54%), less than GelStat Corporation (0%), less than Pacira BioSciences, Inc. (27.39%), less than Collegium Pharmaceutical, Inc. (8.29%), less than Prestige Consumer Healthcare Inc. (46.81%), less than Incannex Healthcare Limited (13.35%), greater than Phibro Animal Health Corporation (-66.75%), less than Shuttle Pharmaceuticals Holdings, Inc. (4.81%), greater than Mallinckrodt plc (-151.81%), greater than Organogenesis Holdings Inc. (-117.04%), less than Lucy Scientific Discovery Inc. (5.34%), greater than Alimera Sciences, Inc. (-377.80%), greater than null (-47.09%),
| Company | ROE | Market cap |
|---|---|---|
| -14.22% | $13.64M | |
| -39.17% | $159.93M | |
| 123.14% | $106.70K | |
| 4.41% | $74.29M | |
| 11.03% | $314.85K | |
| -16.27% | $43.97M | |
| -117.54% | $5.63M | |
| 0% | $185.39K | |
| 27.39% | $932.32M | |
| 8.29% | $1.18B | |
| 46.81% | $3.51B | |
| 13.35% | $38.22M | |
| -66.75% | $764.71M | |
| 4.81% | $7.39M | |
| -151.81% | $4.52M | |
| -117.04% | $429.53M | |
| 5.34% | $906.91K | |
| -377.80% | $293.47M | |
| -47.09% | $0 |
Build a custom stock screener for Amryt Pharma plc (AMYT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Amryt Pharma plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Amryt Pharma plc (AMYT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Amryt Pharma plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Amryt Pharma plc's ROE?
How is the ROE calculated for Amryt Pharma plc (AMYT)?
What is the highest ROE for Amryt Pharma plc (AMYT)?
What is the 3-year average ROE for Amryt Pharma plc (AMYT)?
What is the 5-year average ROE for Amryt Pharma plc (AMYT)?
How does the current ROE for Amryt Pharma plc (AMYT) compare to its historical average?